Oregon State University scientists have found a way to more than double the uptake ability of a chemical structure that can be used for scrubbing carbon dioxide from factory flues.

The Mohammad Seyedsayamdost lab’s approach could herald a shift in the way we use antibiotics. By attacking the pathogen’s unique and hidden metabolic “vulnerabilities,” researchers offers a new tool in the global challenge to counteract antibiotic resistance and uncover similar combination therapies for other diseases.

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder associated with liver disease, ranging from fibrosis to hepatocellular carcinoma. The disease remains asymptomatic until its final stages when liver transplantation is the only available therapy. Biomarkers offer an advantage for disease evaluation. The presence of microRNAs (miRNAs) in plasma extracellular vesicles (EVs) presents a noninvasive approach to assess the molecular signatures of the disease. In this study, we aimed to identify miRNA biomarkers to distinguish molecular signatures of the liver disease associated with AATD in AATD individuals.

Physicists, led by the University of Bath in the UK, are getting closer to controlling single-molecule chemical reactions – could this shape the future of pharmaceutical research?

A study led by the University of Barcelona and the Spanish National Research Council’s Institute for Advanced Chemistry of Catalonia (IQAC - CSIC) presents a new therapeutic tool capable of inhibiting the proliferation of the SARS-CoV-2 virus that causes COVID-19. The results open up new perspectives in the fight against this coronavirus and other viral diseases that still have no medical treatment, such as the Crimean-Congo haemorrhagic fever (CCHFV).